Nicholas A. Saccomano - 22 Sep 2025 Form 4 Insider Report for OnKure Therapeutics, Inc. (OKUR)

Role
President and CEO, Director
Signature
/s/ Rogan Nunn, by power of attorney
Issuer symbol
OKUR
Transactions as of
22 Sep 2025
Net transactions value
-$231
Form type
4
Filing time
24 Sep 2025, 19:42:17 UTC
Previous filing
25 Jun 2025
Next filing
23 Dec 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Nicholas A. Saccomano filed Form 4 for OnKure Therapeutics, Inc. (OKUR) on 24 Sep 2025."

Quick Takeaways

  • This page summarizes Nicholas A. Saccomano's Form 4 filing for OnKure Therapeutics, Inc. (OKUR).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Filing timestamp: 24 Sep 2025, 19:42.

What Changed

  • Previous filing in this sequence was filed on 25 Jun 2025.
  • Current net transaction value: -$231.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Saccomano Nicholas A President and CEO, Director C/O ONKURE THERAPEUTICS, INC., 6707 WINCHESTER CIRCLE, SUITE 400, BOULDER /s/ Rogan Nunn, by power of attorney 24 Sep 2025 0001609284

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OKUR Class A Common Stock Sale $231 -88 -2.4% $2.62 3,506 22 Sep 2025 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"), pursuant to the terms of the Issuer's 2023 RSU Equity Incentive Plan.
F2 This transaction was executed in multiple trades at prices ranging from $2.60 to $2.645. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Sponsored